Sub-Tenon Triamcinolone and Anti-HIV Medication–Induced Cushing Syndrome
Boonkit Purt,Alexander Nugent,Patricia S. Wu,Yannis M. Paulus
DOI: https://doi.org/10.1001/jamaophthalmol.2024.3284
IF: 8.253
2024-10-18
JAMA Ophthalmology
Abstract:We describe a patient who developed Cushing syndrome associated with periodic sub-Tenon triamcinolone injections in the setting of using ritonavir (Norvir [AbbVie]) and darunavir (Prezista [Janssen]), 2 protease inhibitors used to treat HIV. We report a patient with a severe adverse effect associated with periodic sub-Tenon triamcinolone injections (STK). The patient is an 82-year-old male with a longstanding history of hereditary chorioretinopathy and pseudophakia for 6 years, who initially presented with a visual acuity with correction of 20/150 OD and 20/60 −2 OS. There was no cell in the anterior or posterior segment. Optical coherence tomography (OCT) showed cystoid macular edema (CME) (Figure 1). Fluorescein angiography demonstrated retinal vascular leakage in the macula with fluorescein accumulation in a petaloid pattern surrounding the fovea, consistent with postsurgical CME (Irvine-Gass) syndrome in both eyes. There was some consideration that the CME was associated with ellipsoid-zone or retinal pigment epithelial disruption associated with his hereditary chorioretinopathy, but there was no evidence of ellipsoid-zone–retinal pigment epithelial disruption (Figure 1). Medical history included type 1 diabetes, congestive heart failure, hypertension, and HIV infection. Medications included darunavir, ritonavir, furosemide, insulin, and apixaban. There was no change in CME after 3 months of topical ketorolac, 0.5%, administered 6 times daily and topical prednisolone acetate, 1%, administered 4 times daily. He then received STK, 20 mg, in each eye, which resulted in improvement in visual acuity to 20/40 OD and 20/40 OS and reduced OCT CME thickness. Within 2 months of starting STK, the patient started having progressively worsening exercise tolerance, dyspnea on exertion, lower extremity weakness, increased fat in his face and abdomen, easy bruising, muscle wasting, and confusion. He continued to receive STK, 20 mg, in each eye every 3 months, for a total of 3 doses in each eye. One month after the third dose of STK, the patient was seen in the emergency department for progression of all his symptoms including skin atrophy (Figure 2) and admitted for further evaluation.
ophthalmology